

# MEDICAL POLICY



<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15,</b> <b>03/17/16, 03/16/17, 03/15/18</b>
<b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>PAGE: 1 OF: 6</b>
<ul style="list-style-type: none"><li>• <i>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i></li><li>• <i>If a commercial product, including an Essential Plan product, covers a specific service, medical policy criteria apply to the benefit.</i></li><li>• <i>If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i></li></ul>	

## **POLICY STATEMENT:**

Based on our criteria and review of the peer-reviewed literature, T-Wave Alternans testing has not been proven to be medically effective and is considered **investigational** for all indications including, but not limited to, risk stratification for ventricular arrhythmias or identifying candidates for electrophysiologic testing or ICD implantation.

*Refer to Corporate Medical Policy #2.01.02 regarding Signal Averaged Electrocardiogram (SAECG).*

*Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.*

## **POLICY GUIDELINES:**

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

## **DESCRIPTION:**

Microvolt T-wave alternans (TWA) refers to a beat-to-beat variability in the amplitude and morphology of the ECG measurement of repolarization in the ST segment and T-wave. A routine electrocardiogram (EKG) cannot detect these small fluctuations, and thus this test requires specialized sensors to detect the fluctuations and computer algorithms to evaluate the results. T-wave alternans is a provocative test that requires gradual elevation of the heart rate to above 110 beats per minute. The test can be performed in conjunction with an exercise tolerance stress test. Test results are reported as the number of standard deviations by which the peak signal of the T-wave exceeds the background noise. This number is referred to as the "alternans ratio." An alternans ratio of 3 or greater is typically considered a positive result, an absent alternans ratio is considered a negative result, and anything in between is considered indeterminate.

The presence of T-wave alternans has been investigated as a risk factor-for ventricular arrhythmias or sudden cardiac death in patients with a history of myocardial infarction, congestive heart failure, or cardiomyopathy. Studies of T-wave alternans have focused on the predictive capability of this test for determining which patients are most likely to benefit from invasive electrophysiologic testing, to select patients for implantable cardioverter/defibrillator therapy (ICD), or as a means for adjusting cardiac pharmacotherapy. T-wave alternans has also been investigated as a diagnostic test for patients with syncope of unknown origin.

Recent primary prevention ICD trials (e.g., MADIT-II and SCD-HeFT) have changed the perspective on selection and risk stratification for use of implantable defibrillators. Given the results of these clinical trials, it is proposed that TWA testing could be a useful or efficient maneuver in improving identification of patients who benefit or do not benefit from ICD implantation.

## **RATIONALE:**

The Heartwave™ Alternans Processing System (Cambridge Heart, Inc.) received 510(K) clearances in 2002 as a system to perform microvolt T-wave alternans (MTWA) testing.

Although T-Wave alternans has been studied as a technique of risk stratification for fatal arrhythmias and sudden cardiac death in patients with a history of MI, CHF, cardiomyopathy and other conditions, there are no clinical studies that conclusively demonstrate how this information can be used in the management of the patient. There are no

<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>  <b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15</b> <b>03/17/16, 03/16/17, 03/15/18</b> <b>PAGE: 2 OF: 6</b>
---	---

randomized trials of either ICDs or antiarrhythmic therapy that have relied on the results of T-wave alternans as a patient selection criterion.

A June 2005 BCBS Association TEC Assessment evaluated the use of Microvolt T-wave alternans for two patient indications:

- I. Patients eligible for ICD placement for primary prevention of sudden death, and
- II. Patients who were not eligible for ICD placement.

The 2005 TEC Assessment noted that patients who have experienced a life-threatening arrhythmia are already at high risk and probably would not require T-wave alternans testing for consideration of ICD implantation (secondary prevention). Eighteen studies were identified using T-wave alternans to prospectively stratify the risk of a subsequent event (n=2,931). For patients who would not otherwise be eligible for ICD placement, TEC noted T-wave alternans would be used for its positive predictive value to select patients who might be at increased risk of VTE and possibly benefit from ICD. In nine studies that reported positive predictive value (PPV), values varied widely from 7 to 67%. In conclusion, TEC found the evidence is insufficient to determine whether the use of T-wave alternans improves net health outcome or whether it is as beneficial as any established alternative. Therefore, the use of T-wave alternans testing for risk stratifying patients being considered for ICD therapy for primary prevention of sudden death did not meet the TEC criteria.

A November 2006 BCBSA TEC Assessment reviewed a smaller number of studies directly relevant to the question of whether microvolt T-wave alternans (MTWA) can identify patients who would otherwise meet clinical indications for ICD therapy but whose risk of death is so low that they would not benefit from treatment. The critical piece of data is the absolute risk of arrhythmia or sudden death in those persons who have a negative T-wave alternans test, and whether it can be determined whether this risk is consistent with no potential benefit from ICD therapy. TEC concluded that the evidence is insufficient to establish what level of risk of events precludes benefit from ICD therapy. Although MTWA testing did risk-stratify patients in these studies, this may not translate to clinical utility, those with negative tests still had arrhythmic events and deaths. All-cause mortality for patients testing MTWA negative varied from 3.8% to 12.5% over 2 years, which was lower than for patients testing MTWA non-negative. Various arrhythmic event outcomes also varied between studies. Arrhythmic events varied from 0% to 5.7% over 2 years in MTWA negative patients, depending on the specific outcome studied. Given the lack of randomized clinical trials, the argument for use of MTWA testing to select patients who might not benefit from ICD therapy rests on two types of information - knowledge of the natural history of persons with MTWA-negative tests, and knowledge of the degree of risk that would confer no benefit from ICD therapy. TEC concluded that the knowledge base for both issues is insufficient.

A modeling study by Chan and colleagues (2006) assumed a 2.7% annual sudden death rate among MTWA-negative patients, and calculated that patients would still benefit from ICD therapy. Although modeling studies are not definitive, this study suggests that even the lower risk of arrhythmia in MTWA-negative patients is not low enough to preclude some benefit from ICD therapy.

The ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death give MTWA a Class IIA recommendation: "It is reasonable to use T-wave alternans for improving the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk for developing life-threatening ventricular arrhythmias". However, a category II recommendation indicates conflicting or divergent evidence, and the "A" qualifier indicates that the weight of opinion is in favor of usefulness or efficacy. The document provides no further description of patients who are at risk. Patients with known ventricular arrhythmias are not really appropriate candidates for MTWA, as they are at sufficiently high risk for sudden death that no further risk assessment is necessary.

Between June 2001 and July 2004, the T-Wave Alternans in Patients with Heart Failure (ALPHA) Registry enrolled 446 patients with NYHA class II and III heart failure and LVEF less than or equal to 40% from nine centers across Italy. Heart failure etiologies included idiopathic dilated cardiomyopathy (n=326), hypertensive cardiomyopathy (n=72), valvular causes (n=9), and others (n=39). The primary endpoint was a composite of cardiac death and life-threatening

<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>  <b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15</b> <b>03/17/16, 03/16/17, 03/15/18</b> <b>PAGE: 3 OF: 6</b>
---	---

ventricular arrhythmias. MTWA results were negative in 34.6% and non-negative in 65.4% (44.8% positive, 20.6% indeterminate). The primary endpoint occurred in 29 of 292 (9.9%) with non-negative results, compared to four of 154 (2.6%) in the negative group. A survival model attempting to adjust for between-group differences in prognostic factors yielded a relative hazard of 4.0 (95% CI: 1.2 to 13.3). The test's negative predictive value through 18 months follow-up was 97.3% (95% CI: 95.4 to 99.8). Thirty-three patients with non-negative and six with negative results received ICDs. In sensitivity analyses accounting for the impact of ICD implantation on differential event occurrence found similar results; those with ICDs had more events recorded. These findings are consistent with most prior observational research finding negative MTWA results associated with fewer arrhythmic outcomes in nonischemic cardiomyopathy (the unpublished ScD-HEFT data being an exception). Limitations of the study include lack of a randomized comparison or using MTWA results to direct ICD placement, and QRS duration. Although the investigators attempted to control for imbalances, the number of events (n=33) was insufficient to obtain valid estimates while accounting for more than a single prognostic factor or variable reflected in the wide confidence intervals. For these reasons, few conclusions can be drawn from the results.

While results from observational studies such as Bloomfield, et al (2006) are suggestive (with its high negative predictive value), the question is whether patients with normal (MTWA-negative) results can safely have an ICD withheld. A definitive answer requires either: 1) a controlled trial in which participants are stratified by MTWA result and the low-risk group randomized to ICD or no ICD or, 2) a well-designed prospective cohort study of patients undergoing ICD placement having MTWA testing conducted prior to placement. Whether MTWA testing can be used to effectively risk-stratify prior to ICD placement should await results of appropriately conducted observational studies and/or clinical trials currently underway. The available studies do not demonstrate that MTWA testing can improve health outcomes.

**CODES:**      Number                      Description

*Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

**CPT:**                      93025 (E/I)                      Microvolt T-wave alternans for assessment of ventricular arrhythmias

*Copyright © 2018 American Medical Association, Chicago, IL*

**HCPCS:**                      No specific codes

**Investigational for all codes**

**ICD10:**                      I21.3-I22.9                      Acute myocardial infarction (code range)  
   I25.2                                      Old myocardial infarction  
   I25.10-I25.119                      Coronary atherosclerosis (code range)  
   I42.0-I43                                      Cardiomyopathy (code range)

**REFERENCES:**

\*Baravelli M, et al. Predictive significance for sudden death of microvolt-level T wave alternans in New York Heart Association class II congestive heart failure patients: a prospective study. *Int J Cardiol* 2005 Oct 20;105(1):53-7.  
Bloomfield DM, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. *J Am Coll Cardiol*. 2006 Jan 17;47(2):456-63.  
\*BlueCross BlueShield Association. T-Wave alternans. Medical Policy Reference Manual Policy #2.02.13. 2013 May 9.

<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>  <b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15</b> <b>03/17/16, 03/16/17, 03/15/18</b> <b>PAGE: 4 OF: 6</b>
---	---

\*BlueCross BlueShield Association Technology Evaluation Center (TEC). Microvolt T-wave alternans testing to risk stratify patients being considered for ICD therapy for primary prevention of sudden death. 2005 Jun (20).

BlueCross BlueShield Association Technology Evaluation Center (TEC) Bulletin. Microvolt T-wave alternans testing to risk stratify patients being considered for ICD therapy for primary prevention of sudden death. 2007 May;24(1).

Cantillon DJ, et al. Predictive value of microvolt T-wave alternans in patients with left ventricular dysfunction. J Am Coll Cardiol 2007 Jul 10;50(2):166-73.

Chan PS, et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 2006 Jul 4;48(1):112-21.

Chan PS, et al. Prognostic implication of redefining indeterminate microvolt T-wave alternans studies as abnormal or normal. Am Heart J 2007 Apr;153(4):523-9.

Chan PS, et al. Do beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol 2010 Sep;21(9):1009-14.

Chauhan VS, et al. Utility of microvolt T-wave alternans to predict sudden cardiac death in patients with cardiomyopathy. Curr Opin Cardiol 2007 Jan;22(1):25-32.

Chow T, et al. Microvolt T-wave alternans for ventricular arrhythmia risk stratification. Expert Rev Cardiovasc Ther 2008 Jul;6(6):833-42.

Chow T, et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol 2008 Nov 11;52(20):1607-15.

Chow T, et al. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 2007 Jan 2;49(1):50-8.

Chow T, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol 2006 May 2;47(9):1820-7.

Costantini O, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009 Feb 10;53(6):471-9.

De Ferrari GM, et al. T-wave alternans in risk stratification of patients with nonischemic dilated cardiomyopathy: can it help to better select candidates for ICD implantation? Heart Rhythm 2009 Mar;6(3 Suppl):S29-35.

Exner DV, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 2007 Dec 11;50(24):2275-84.

Filion KB, et al. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study. Int J Technol Assess Health Care 2009 Apr;25(2):151-60.

Garcia EV. T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies. Ann Noninvasive Electrocardiol 2008 Oct;13(4):401-20.

Gold MR, et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation 2008 Nov 11;118(20):1022-8.

\*Gold MR, et al. A comparison of T-wave alternans, SAECG, and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Card 2000 Dec;36(7):2247-53.

\*Grimm W. et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circ 2003 Dec 9;108(23):2883-91.

<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>  <b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15</b> <b>03/17/16, 03/16/17, 03/15/18</b> <b>PAGE: 5 OF: 6</b>
---	---

\*Hohnloser SH, et al T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet 2003 Jul 12;362(9378):125-6.

Hohnloser SH, et al. Evidence regarding clinical use of microvolt T-wave alternans. Heart Rhythm 2009 Mar;6(3 Suppl):S36-44.

\*Huikuri HV, et al. Cardiac arrhythmias and risk stratification after myocardial infarction: results of the CARISMA pilot study. Pacing Clin Electrophysiol 2003 Jan;26(1 Pt 2):416-9.

\*Huikuri HV, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003 Aug 20;42(4):652-8.

Kreuz J, et al. Modern noninvasive stratification in primary prevention of sudden cardiac death. J Interv Card Electrophysiol 2008 Oct;23(1):23-8.

Maeda S, et al. Ambulatory ECG-based T-wave alternans and heart rate turbulence predict high risk arrhythmic events in patients with old myocardial infarction. Circ J 2009 Dec;73(12):2223-8.

\*Marcus F, et al Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design and protocol. Circ 2003 Jun 17;107(23):2975-8.

Minkinen M, et al. Impaired exercise capacity predicts sudden cardiac death in low-risk population: enhanced specificity with heightened T-wave alternans. Ann Med 2009 Mar 19:1-11.

Minkinen M, et al. Enhanced predictive power of quantitative TWA during exercise testing in the Finnish Cardiovascular Study. J Cardiovasc Electrophysiol 2009 Apr;20(4):408-15.

Narayan SM. T-wave alternans testing for ventricular arrhythmias. Prog Cardiovasc Dis 2008 Sep-Oct;51(2):118-27.

Narayan SM, et al. T-wave alternans, restitution of human action potential duration, and outcome. J Am Coll Cardiol 2007 Dec 18;50(25):2385-92.

Nieminen T, et al. T-wave alternans predicts mortality in a population undergoing a clinically indicated exercise test. Eur Heart J 2007 Oct;28(19):2332-7.

Salerno-Uriarte JA, et al. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol 2007 Nov 6;50(19):1896-904.

Schmitt J, et al. Assessment of microvolt T-wave alternans in high-risk patients with the congenital long-QT syndrome. Ann Noninvasive Electrocardiol 2009 Oct;14(4):340-5.

Stein PK, et al. Ambulatory ECG-based T-wave alternans predicts sudden cardiac death in high-risk post-MI patients with left ventricular dysfunction in the EUPHESUS study. J Cardiovasc Electrophysiol 2008 Oct;19(10):1037-42.

Tasic J, et al. T-wave variability as a risk stratifier in patients with dilated cardiomyopathy. Pacing Clin Electrophysiol 2009 Mar;32 (Suppl1):S155-7.

\*Turrini P, et al. Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy. Ann Noninvasive Electrocardiol 2003 Apr;8(2):161-9.

Van der Avoort CJ, et al. Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left-ventricular dysfunction: a systematic review and meta-analysis. BMC Cardiovasc Disord 2009 Jan 28;9-5.

\*Verrier RL, et al. Ambulatory electrocardiogram-based tracking of T wave alternans in postmyocardial infarction patients to assess risk of cardiac arrest or arrhythmic death. J Cardiovasc Electrophysiol 2003 Jul;14(7):705-11.

Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop

<b>SUBJECT: MICROVOLT T-WAVE ALTERNANS</b>  <b>POLICY NUMBER: 2.01.45</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 07/20/06</b> <b>REVISED DATE: 08/16/07, 07/17/08, 06/18/09, 05/27/10</b> <b>ARCHIVED DATE: 04/21/11</b> <b>EDITED DATE: 04/19/12, 04/18/13, 04/17/14, 03/19/15</b> <b>03/17/16, 03/16/17, 03/15/18</b> <b>PAGE: 6 OF: 6</b>
---	---

Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006 Sep 5;48(5):e247-346.

\* Key article

**KEY WORDS:**

MTWA, Risk stratification.

---



---

## CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

---



---

There is currently a National Coverage Determination (NCD) for Microvolt T-Wave Alternans (MTWA). Please refer to the following NCD website for Medicare Members: <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=310&ncdver=2&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Upstate&CptHcpcsCode=36514&bc=gAAAABAAAA&>.

There is also a recently published decision memo (1/13/15) addressing MTWA using the modified moving average (MMA) method. The Centers for Medicare & Medicaid Services has decided that no National Coverage Determination (NCD) is appropriate at this time for microvolt T-wave alternans (MTWA) testing using the modified moving average (MMA) method for the evaluation of patients at risk for sudden cardiac death (SCD). National non-coverage will be removed. Medicare coverage of MTWA using the MMA method will be determined by the local contractors. <http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=275>.